Human Genome Denies Hiding Suicide Risks In Lupus Drug Case
Biopharmaceutical firm Human Genome Sciences Inc. on Thursday asked a federal judge to scuttle proposed securities class actions accusing it of concealing suicide risks associated with lupus drug Benlysta, saying that...To view the full article, register now.
Already a subscriber? Click here to view full article